Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma.

The mouse myoblast C2C12 cell line transfected singly with cDNA for Pax-3, PAX3-FKHR, or insulin-like growth factor (IGF) II or cotransfected with IGF-II plus Pax-3 or with IGF-II plus PAX3-FKHR genes showed an altered morphology, a lack of differentiation, and higher proliferation rates in vitro. On s.c. injection into nude mice, tumors grew from transfected cell lines but not from cells transfected with the empty vector. Tumors derived from IGF-II/PAX3-FKHR- and IGF-II-transfected cells grew most rapidly. Cotransfection of IGF-II plus Pax-3 induced tumors comprised highly differentiated striated muscle cells; Pax-3, PAX3-FKHR, or IGF-II transfection produced tumors at varying stages of differentiation. Tumors derived from IGF-II plus PAX3-FKHR-cotransfected cells were composed of undifferentiated cells. This was the only tumor type to infiltrate the underlying muscle. The most angiogenesis and the least apoptosis were observed in the latter tumors. These results support the hypothesis that PAX3-FKHR interacts with IGF-II to play a critical role in the oncogenesis of rhabdomyosarcoma.

[1]  G. Cossu,et al.  Redefining the Genetic Hierarchies Controlling Skeletal Myogenesis: Pax-3 and Myf-5 Act Upstream of MyoD , 1997, Cell.

[2]  S. Koester,et al.  Ectopic Pax-3 Activates MyoD and Myf-5 Expression in Embryonic Mesoderm and Neural Tissue , 1997, Cell.

[3]  Eva L Feldman,et al.  Insulin-like Growth Factors as Regulators of Cell Motility Signaling Mechanisms , 1997, Trends in Endocrinology & Metabolism.

[4]  J R Florini,et al.  Growth hormone and the insulin-like growth factor system in myogenesis. , 1996, Endocrine reviews.

[5]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[6]  F. Barr,et al.  Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Fletcher,et al.  Soft Tissue Tumors , 1995, Current Topics in Pathology.

[8]  F. Barr,et al.  Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. , 1995, Oncogene.

[9]  J. Epstein,et al.  Pax3 Inhibits Myogenic Differentiation of Cultured Myoblast Cells (*) , 1995, The Journal of Biological Chemistry.

[10]  F. Barr,et al.  The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3 , 1995, Molecular and cellular biology.

[11]  L. Helman,et al.  Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[12]  B. Schäfer,et al.  Molecular cloning and characterization of a human PAX-7 cDNA expressed in normal and neoplastic myocytes. , 1994, Nucleic acids research.

[13]  A. Haworth,et al.  PCR amplification of 40-year-old paraffin-embedded tumor-tissues - comparison of 4 different DNA extraction and purification methods. , 1994, International journal of oncology.

[14]  S. Zhan,et al.  Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. , 1994, The Journal of clinical investigation.

[15]  M. Goulding,et al.  Regulation of Pax-3 expression in the dermomyotome and its role in muscle development. , 1994, Development.

[16]  B. Williams,et al.  Pax-3 expression in segmental mesoderm marks early stages in myogenic cell specification. , 1994, Development.

[17]  H. Arnold,et al.  Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells. , 1994, Development.

[18]  G. Evan,et al.  Oncogenes and cell death. , 1994, Current opinion in genetics & development.

[19]  L. Helman,et al.  Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. , 1994, American journal of clinical pathology.

[20]  J. Downing,et al.  Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. , 1993, Cancer research.

[21]  B. Emanuel,et al.  Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma , 1993, Nature Genetics.

[22]  J. Biegel,et al.  Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma , 1993, Nature Genetics.

[23]  S. Chiou,et al.  Insulin-like growth factor I stimulates transcription of the c-jun proto-oncogene in Balb/C 3T3 cells. , 1992, Biochemical and biophysical research communications.

[24]  M. Goulding,et al.  Pax‐3, a novel murine DNA binding protein expressed during early neurogenesis. , 1991, The EMBO journal.

[25]  A. Efstratiadis,et al.  Parental imprinting of the mouse insulin-like growth factor II gene , 1991, Cell.

[26]  A. Perkins,et al.  Homeobox gene expression plus autocrine growth factor production elicits myeloid leukemia. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Florini,et al.  Highly specific inhibition of IGF-I-stimulated differentiation by an antisense oligodeoxyribonucleotide to myogenin mRNA. No effects on other actions of IGF-T. , 1990, The Journal of biological chemistry.

[28]  E. Rutanen,et al.  Insulin-like growth factors and their binding proteins. , 1990, Acta endocrinologica.

[29]  E. Kohn,et al.  Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[30]  K. Hall,et al.  Insulin-like growth factors and their binding proteins. , 1990, Physiological reviews.

[31]  C. Potten,et al.  Response of intestinal cells of differing topographical and hierarchical status to ten cytotoxic drugs and five sources of radiation. , 1983, British Journal of Cancer.

[32]  J. Stephenson,et al.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia , 1982, Nature.

[33]  P. Porcu,et al.  Oncogenes, growth factors and control of the cell cycle. , 1993, Cancer surveys.

[34]  P. Houghton,et al.  A specific chromosomal abnormality in rhabdomyosarcoma. , 1987, Cytogenetics and cell genetics.